EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   7.3.2.7 | Cardiomyopathies |
31461301 |
Biallelic Variants in ASNA1, Encoding a Cytosolic Targeting Factor of Tail-Anchored Proteins, Cause Rapidly Progressive Pediatric Cardiomyopathy. |
causal interaction
unassigned |
4
0 |
| 7.3.2.7 | Cardiomyopathies |
32543991 |
Correction to: Biallelic Variants in ASNA1, Encoding a Cytosolic Targeting Factor of Tail-Anchored Proteins, Cause Rapidly Progressive Pediatric Cardiomyopathy. |
unassigned |
0 |
| 7.3.2.7 | Hypersensitivity |
20966125 |
ASNA-1 activity modulates sensitivity to cisplatin. |
causal interaction
therapeutic application
unassigned |
2
4
0 |
| 7.3.2.7 | Immune System Diseases |
30192896 |
Comparative transcriptome analysis of Eriocheir japonica sinensis response to environmental salinity. |
unassigned |
0 |
| 7.3.2.7 | Melanoma |
18478230 |
ASNA1, an ATPase targeting tail-anchored proteins, regulates melanoma cell growth and sensitivity to cisplatin and arsenite. |
diagnostic usage
ongoing research
therapeutic application
unassigned |
3
4
1
0 |
| 7.3.2.7 | Neoplasms |
20966125 |
ASNA-1 activity modulates sensitivity to cisplatin. |
causal interaction
therapeutic application
unassigned |
2
4
0 |
| 7.3.2.7 | Neoplasms |
24058864 |
Depletion of the ER chaperone ENPL-1 sensitizes C. elegans to the anticancer drug cisplatin. |
causal interaction
unassigned |
1
0 |
| 7.3.2.7 | Ovarian Neoplasms |
19724867 |
Increased sensitivity to platinating agents and arsenite in human ovarian cancer by downregulation of ASNA1. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
1
4
3 |
| 7.3.2.7 | Tuberculosis |
20947511 |
Novel channel-enzyme fusion proteins confer arsenate resistance. |
unassigned |
0 |
